Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$4.18
-6.7%		$5.65
$2.80
▼
$8.97
$150.72M0.6337,931 shs1.37 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
+2.99%+5.41%-18.62%-57.50%-54.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$4.18
-6.7%		$5.65
$2.80
▼
$8.97
$150.72M0.6337,931 shs1.37 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
+2.99%+5.41%-18.62%-57.50%-54.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/AN/A-29.62%-28.20%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Institutional Ownership

CompanyInstitutional Ownership
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

Meet the Silverback, the Leader of the Troop
October 17, 2024  |  pbs.orgP
10 Fun Facts About Mountain Gorillas
September 18, 2024  |  nationalgeographic.comN
CapstanTx secures $165 million to deliver precise in vivo cell engineering
July 28, 2024  |  pharmaphorum.comP
ARS Pharmaceuticals Inc (SPRY)
May 11, 2023  |  uk.investing.comhttps://uk.investing.com/equities/silverback-therapeutics-inc
Wild Isles
March 12, 2023  |  wwf.org.ukW
A look back at RNA Therapeutics – day one
February 23, 2023  |  pharmaphorum.comP
SPRY ARS Pharmaceuticals, Inc.
January 24, 2023  |  seekingalpha.comhttps://seekingalpha.com/symbol/SPRY
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
November 22, 2022  |  247wallst.comhttps://247wallst.com/investing/2022/11/22/ars-pharma-ceo-richard-lowenthal-holds-8-silverback-stake-after-merger/
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
November 18, 2022  |  nasdaq.comhttps://www.nasdaq.com/articles/dr.-sarina-tanimoto-discloses-position-in-sbtx-silverback-therapeutics
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 10, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-announces-presentation-clinical-130000987.html?.tsrc=rss
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
November 8, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-closes-merger-silverback-210200048.html?.tsrc=rss
Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
October 28, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/silverback-fda-accepts-ars-pharm-s-nda-for-neffy-for-treatment-of-allergic-reactions-1031824142
FDA accepts ARS Pharma’s NDA for Neffy
October 24, 2022  |  thepharmaletter.comT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI
October 23, 2022  |  kentuckytoday.comK
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
October 21, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/silverback-therapeutics-inc-announces-fda-113100379.html?.tsrc=rss
Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?
October 19, 2022  |  aaii.comA
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN
October 12, 2022  |  bakersfield.comB
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
September 17, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/investigation-alert-halper-sadeh-llc-investigates-cvet-sbtx-irbt-1031746211
SBTX Silverback Therapeutics, Inc.
September 15, 2022  |  seekingalpha.comhttps://seekingalpha.com/symbol/SBTX/charting
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
September 6, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/shareholder-notice-halper-sadeh-llp-investigates-ftai-sbtx-cvet-gbt-1031726462
Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$4.18 -0.30 (-6.70%)
As of 09/23/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas